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Abstract
Introduction: Response to trastuzumab in metastatic breast cancer correlates with expression of the high binding
variant (158V) of the activating Fcg receptor IIIA (CD16A). We engineered MGAH22, a chimeric anti-HER2
monoclonal antibody with specificity and affinity similar to trastuzumab, with an Fc domain engineered for
increased binding to both alleles of human CD16A.
Methods: MGAH22 was compared to an identical anti-HER2 mAb except for a wild type Fc domain. Antibody-
dependent cell cytotoxicity (ADCC) assays were performed with HER2-expressing cancer cells as targets and human
PBMC or purified NK cells as effectors. Xenograft studies were conducted in mice with wild type murine FcgRs; in
mice lacking murine CD16; or in mice lacking murine CD16 but transgenic for human CD16A-158F, the low-
binding variant. The latter model reproduces the differential binding between wild type and the Fc-optimized mAb
for human CD16A. The JIMT-1 human breast tumor line, derived from a patient that progressed on trastuzumab
therapy, was used in these studies. Single and repeat dose toxicology studies with MGAH22 administered
intravenously at high dose were conducted in cynomolgus monkeys.
Results: The optimized Fc domain confers enhanced ADCC against all HER2-positive tumor cells tested,
including cells resistant to trastuzumab’s anti-proliferative activity or expressing low HER2 levels. The greatest
improvement occurs with effector cells isolated from donors homozygous or heterozygous for CD16A-158F,
the low-binding allele. MGAH22 demonstrates increased activity against HER2-expressing tumors in mice
transgenic for human CD16A-158F. In single and repeat-dose toxicology studies in cynomolgus monkeys, a
species with a HER2 expression pattern comparable to that in humans and Fcg receptors that exhibit enhanced
binding to the optimized Fc domain, MGAH22 was well tolerated at all doses tested (15-150 mg/kg) and
exhibited pharmacokinetic parameters similar to that of other anti-HER2 antibodies. Induction of cytokine
release by MGAH22 in vivo or in vitro was similar to that induced by the corresponding wild type mAb or
trastuzumab.
Conclusions: The data support the clinical development of MGAH22, which may have utility in patients with low
HER2 expressing tumors or carrying the CD16A low-binding allele.
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HER2, an overexpressed cell-surface oncoprotein that
contributes to breast, gastric, and other cancers [1], is a
validated therapeutic target, as evidenced by clinical suc-
cess of the monoclonal antibody (mAb) trastuzumab
[2-5]. Trastuzumab acts against HER2-positive tumors
by multiple mechanisms, including receptor internaliza-
tion, receptor ‘shedding’, direct anti-proliferative activity,
antibody-dependent cell-mediated cytotoxicity (ADCC),
and presentation of antigenic determinants of opsonized
cells to antigen-presenting cells [6]. The latter mechan-
isms depend upon the interaction of the Fc domain of
trastuzumab with Fc-gamma receptors (FcgRs) expressed
by immune effector populations, such as natural killer
(NK) cells or mononuclear phagocytes [7-10]. Poly-
morphic variants of certain activating FcgRs predict
response duration to trastuzumab: patients homozygous
for CD16A (FcgRIIIA) 158V allele or CD32A (FcgRIIA)
131H allele or both have longer progression-free survival
than patients carrying the respective 158F or 131R
alleles [11], which bind the Fc domain of immunoglobu-
l i nG1( I g G 1 ) ,t h em a i nc l a s so ft h e r a p e u t i cm A b s ,
such as trastuzumab, with lower affinity than their allelic
counterparts.
FcgR polymorphism influences the clinical response to
several IgG1 mAbs other than trastuzumab. While the
relationship between CD16A polymorphism and benefit
is controversial for cetuximab [12-15], CD16-158V and
CD32A-131H homozygosity appear to be associated
with beneficial responses for rituximab and infliximab
[16-18]. Furthermore, for an agonistic anti-death recep-
tor antibody with intrinsic anti-tumor activity that is
potentiated by FcgR interactions, effector cells expres-
sing the higher-binding CD16A and CD32A variants
supported substantially greater proapoptoptic activity
[19]. CD16A-158V homozygotes represent 10% to 20%
of the population worldwide, whereas CD32A-131H
homozygotes represent approximately 25% of Cauca-
sians or Africans and 50% to 60% of Asians [20,21].
Thus, FcgR genotypes most frequently associated with
greater beneficial responses occur in a minority of the
population. This provides a strong rationale for engi-
neering the Fc domain of trastuzumab to better interact
with low-binding alleles of activating FcgRs to expand,
without regard to FcgR genotype, the benefit of treat-
ment to patients.
MGAH22 is an Fc-engineered mAb designed for
increased binding to both alleles of CD16A and preser-
vation of the direct anti-proliferative activity of trastuzu-
mab. Since trastuzumab activity is enhanced in mice
genetically deficient for the inhibitory FcgR, CD32B
(FcgRIIB) [7], a negative regulator of activation of mono-
cytes, macrophages, and dendritic cells [22], the Fc
domain of MGAH22 was also engineered for reduced
CD32B binding. The optimized Fc domain confers
enhanced ADCC activity against HER2-positive tumors,
including low HER2 expressors, independently of the
FcgR variant for the effector cells. MGAH22 is active in
vitro and in vivo against a HER2-positive tumor line
derived from a patient whose tumor progressed while
on trastuzumab. Because changes in effector cell interac-
tions could have safety implications, high-dose
MGAH22 toxicology studies were conducted in cyno-
molgus monkeys, a relevant species, with no significant
antibody-related safety findings.
The enhanced properties of MGAH22 suggest poten-
tial clinical utility in extending the benefit of anti-HER2
immunotherapy to patients independently of their
CD16A allelic expression and to patients who, because
of low HER2 expression levels, do not qualify for trastu-
zumab treatment as well as to patients whose tumors
progress while on trastuzumab.
Materials and methods
Human tumor cell lines
Breast (MCF-7, ZR-75-1, and SKBR-3), gastric (N87),
colon (HT-29), and bladder (SW780) lines were
obtained from the American Type Culture Collection
(Manassas, VA, USA), and JIMT-1 (breast) was obtained
from DSMZ (Braunschweig, Germany). All cell lines
were cultured in accordance with recommended specifi-
cations for fewer than 30 passages. The number of
HER2-binding sites per cell and immunohistochemistry
category (0 to 3+) were determined by flow cytometry
(QuantiBRITE™ P E ;B DB i o s c i e n c e s ,S a nJ o s e ,C A ,
USA) and HercepTest™ (Dako, Carpinteria, CA, USA):
MCF-7 (14,000; 1+), HT-29 (25,000; 1+), SW780
(37,000; 1+), ZR-75-1 (52,000; 2+), JIMT-1 (79,000; 2+);
N87 (270,000; 2+), and SKBR-3 (540,000; 3+).
Antibodies
ch4D5 was generated by fusing synthetic sequences
encoding light- and heavy-chain variable domains of
4D5, the murine precursor of trastuzumab [23], to
human  and IgG1 constant domains, respectively.
RES120 was generated from ch4D5 by light-chain muta-
genesis (N65S) to eliminate a consensus N-glycosylation
site. MGAH22 was generated from RES120 by exchan-
ging its Fc domain for MGFc0264 (L235V, F243L, R292P,
Y300L, and P396L) [24,25]. ch4D5-N297Q, which con-
tains an inactivated Fc domain, was derived from ch4D5
by mutating the heavy-chain N-glycosylation site.
Fc-gamma receptor binding
Binding of soluble forms of FcgRs (either monomeric
extracellular domains or dimeric inactivated Fc-G2
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resonance after capture of antibodies to immobilized
HER2 [25].
In vitro anti-proliferation activity
Tumor cells (2 × 10
4 per well) were incubated for 6
days with antibodies at 37°C, and proliferation/viability
was detected by using the CellTiterGlo Luminescent
Cell Viability Assay Kit (Promega Corporation, Madison,
WI, USA).
Antibody-dependent cell-mediated cytotoxicity
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from healthy human donor blood (Ficoll-Paque™
Plus; GE Healthcare, Piscataway, NJ, USA). NK cells
were purified (Untouched Human NK cell isolation kit;
Dynal, Invitrogen Corporation, Carlsbad, CA, USA).
Target cells (2 × 10
4 per well) were incubated with anti-
bodies for 30 minutes at 37°C in RPMI-1640 (without
phenol red), 10% fetal bovine serum, and 2 mM Gluta-
Max™ (Invitrogen Corporation) before adding effector
cells at an effector/target ratio of 30:1 (PBMCs) or 3:1
(purified NK cells). Lactate dehydrogenase release (Pro-
mega Corporation) was measured after overnight incu-
bation. Cytotoxicity (expressed as a percentage) =
(experimental cell lysis-antibody-independent cell cytoly-
sis)/(maximum target lysis-spontaneous target lysis) ×
100. FcgR genotypes were determined by sequencing
polymerase chain reaction-amplified DNA.
Treatment of xenograft tumors in mice
All mouse experiments were performed at our facility
under protocols approved by the MacroGenics Institu-
tional Animal Care and Use Committee. RAG2
-/- Balb/
cm i c e( W TF c gR mice) were obtained from Taconic
(Rockville, MD, USA). mCD16
-/- RAG2
-/- Balb/c mice
(mCD16 knockouts) and mCD16
-/- hCD16A
+ RAG2
-/-
mice (mCD16 knockouts transgenic for hCD16A-158F)
were bred at MacroGenics. JIMT-1 cells (5 × 10
6 per
mouse) in phosphate-buffered saline plus Matrigel
were implanted subcutaneously and antibodies admi-
nistered intraperitoneally weekly beginning at the time
of tumor implantation or after tumors of approxi-
mately 200 mm
3 had been allowed to form. Tumor
sizes were monitored three times weekly by orthogonal
measurements with electronic calipers. Statistical dif-
ferences in tumor sizes were assessed by two-way ana-
lyses of variance and Bonferroni post-test analyses
(GraphPad Prism 5.02; GraphPad Software, Inc., La
Jolla, CA, USA).
Toxicology/toxicokinetics in non-human primates
Cynomolgus monkey experiments were conducted at
Charles River Laboratories (Sparks, NV, USA) in
accordance with Testing Facility Standard Operating
Procedure, which adheres to the regulations outlined in
the US Department of Agriculture Animal Welfare Act
[26] and the conditions specified in the Guide for the
Care and Use of Laboratory Animals [27]. The study
protocols were approved by the Testing Facility Institu-
tional Animal Care and Use Committee. A single-dose
study was conducted with 12 cynomolgus monkeys ran-
domly assigned to two groups (three per sex per group)
receiving MGAH22 or RES120 at 50 mg/kg by 60-min-
ute intravenous infusion. All animals were euthanized at
day 62 for necropsies. A repeat-dose study was con-
ducted with 40 monkeys randomly assigned to four
groups (five per sex per group) receiving vehicle or
MGAH22 weekly for 6 weeks at 15, 50, or 150 mg/kg
by 60-minute intravenous infusion. Twenty-four (three
per sex per group) were euthanized on day 40, 4 days
after the last dose, and 16 (two per sex per group) were
followed for a recovery period of 56 days and euthanized
on day 93 for necropsies.
Measurement of serum MGAH22 concentration by
enzyme-linked immunosorbent assay
Goat anti-MGAH22-Fv antibody was used to capture
MGAH22 (or RES120) from cynomolgus serum and this
was followed by detection with biotinylated goat anti-
MGAH22-Fv antibody plus streptavidin-alkaline phos-
phatase conjugate and 4-methylumbelliferyl phosphate
as substrate. Product was measured by using a fluores-
cent microplate reader against a standard curve (four-
parameter non-linear curve fitting). The minimum
quantifiable concentration was 4.25 ng/mL.
Measurement of cytokine release
BD™ human Th1/Th2 cytometric bead array (CBA)
and Human IL-5 Flex Set CBA were used to measure
levels of IL-2, IL-4, IL-5, IL-6, IL-10, tumor necrosis
factor-alpha (TNF-a), and interferon-gamma (IFN-g)i n
serum collected at different times after intravenous
administration of antibodies to cynomolgus monkeys.
Statistical differences in relative changes from baseline
were assessed by non-parametric van Elteren tests (an
extension to the Wilcoxon rank-sum test) and Bonfer-
roni adjustments for multiple comparisons (SAS 9.2;
SAS Institute Inc., Cary, NC, USA). Cytokine levels
were also measured in cell culture supernatants after
incubation of human PBMCs with antibodies on plates
left uncoated or coated with 1 μg/mL of HER2 anti-
gen-recombinant human ErbB2/HER2 Fc chimera
(R&D Systems, Inc., Minneapolis, MN, USA), enzyma-
tically deglycosylated-for 16 to 20 hours at 37°C. Sta-
tistical differences in cytokine levels induced by the
different antibodies were assessed by a Wilcoxon
signed rank test (SAS 9.2).
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MGAH22 preserves HER2-binding and anti-proliferative
properties of trastuzumab
MGAH22 is a human/mouse chimeric IgG1 anti-HER2
antibody based on mouse clone 4D5, the precursor of
trastuzumab [23] with an engineered Fc domain
(MGFc0264) similar to the previously described Fc var-
iant 18 [25], except that the V305I mutation was
replaced by L235V to reduce CD32B binding. RES120,
a molecule identical to MGAH22 except for a wild-
type (WT) human IgG1 Fc domain, was used for com-
parison and as a trastuzumab surrogate. MGAH22
preserves the HER2-binding properties of RES120 and
authentic trastuzumab (Figure 1a). Proliferation of
SKBR-3 cells is sensitive to trastuzumab [23], whereas
proliferation of JIMT-1 cells, a line with HER2 gene
amplification but moderate expression and derived
from a breast cancer patient whose metastatic tumor
h a dp r o g r e s s e dw h i l eo nt r a s tuzumab, is insensitive to
trastuzumab [28]. MGAH22, RES120, and trastuzumab
exhibit anti-proliferative activity indistinguishable from
each other against SKBR-3 cells, but none shows activ-
ity against JIMT-1 cells (Figure 1b). Thus, the Fc
domain modifications of MGAH22 do not influence
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Figure 1 HER2-binding and anti-proliferative activity. (a) HER2-binding activity of MGAH22 was compared with RES120 or trastuzumab by
antigen-capture enzyme-linked immunosorbent assay. EC50 (and 95% confidence interval) values were 39.33 (29.45 to 52.52) ng/mL for MGAH22
and 45.75 (33.37 to 62.67) ng/mL for RES120 (left panel) and 28.76 (24.96 to 33.15) for MGAH22 and 27.28 (23.6 to 31.53) ng/mL for trastuzumab
(right panel). (b) Proliferation of JIMT-1 and SKBR-3 cells in the presence of MGAH22, RES120, or trastuzumab. Data are presented as mean ±
standard error of the mean. EC50, effective concentration for 50% binding; MGAH22, chimeric anti-HER2 monoclonal antibody with an optimized
Fc domain; Neg ctrl mAb, negative control monoclonal antibody; RES120, chimeric anti-HER2 monoclonal antibody with wild-type human
immunoglobulin G 1 Fc domain; RLU, relative light units.
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the absence of effector cells.
Binding of the optimized Fc domain to Fc-gamma
receptors
Binding profiles of soluble FcgRs to mAbs with WT or
optimized Fc domains were determined (Figure 2).
Compared with the WT Fc domain, the optimized
MGFc0264 domain demonstrates increased affinity for
both alleles of human CD16A (equilibrium dissociation
constant (KD) for 158V: from 415 nM to 89 nM; KD
for 158F: from 1,059 nM to 161 nM) but decreased
binding to human CD32B, inhibitory FcgR( K D:f r o m
52 nM to 437 nM). It similarly imparts decreased
binding to the 131R allele of human activating FcgR,
CD32A (KD:f r o m3 6n Mt o2 1 8n M ) ,b u tb i n d i n gt o
the 131H allele is not substantially modified (KD:f r o m
39 nM to 34 nM). Owing to the substantially low affi-
nity of human CD32A/B, KD values were obtained for
the bivalent Fc fusion versions of these receptors
(whose Fc domain was inactivated via N297Q or
D265A mutation to eliminate homologous interac-
tions); this strategy provides adequate sensitivity, due
to avidity effects, to determine binding differences. The
optimized Fc domain shows increased binding to
human C1q. Binding to human CD64 (the high-affinity
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Figure 2 Binding of monoclonal antibodies with wild-type or optimized Fc domains to FcgRs. Representative surface plasmon resonance
traces for binding of fixed concentrations of soluble human FcgRs or C1q (a), cynomolgus monkey FcgRs (b), or murine FcgRs (c) to ch4D5
(contains wild-type-Fc domain) or ch4D5-0264 (contains MGFc0264) captured on immobilized recombinant human HER2 protein are shown.
hCD16A-158V, hCD16A-158F, and hCD64 were analyzed as soluble monomeric extracellular domains (ECDs), whereas hCD32A-131R, hCD32A-
131H, and hCD32B were analyzed as soluble dimeric extracellular domain Fc-fusions (FcN297Q or FcD265A). Values of the equilibrium dissociation
constant (KD) from full-range titration studies were determined by the fitting of equilibrium responses to a steady-state affinity model for hCD16
and hCD32 receptors or by a global fit to 1:1 binding model for hCD64 interactions that did not reach a steady state. FcgR, Fc-gamma receptor;
RU, relative units.
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substantially modified.
Compared with either allele of human CD16A, the
WT human Fc domain exhibits increased binding to
cynomolgus monkey CD16A, which has an invariant
isoleucine at position 158 [29]. The optimized Fc
domain imparts further increases in binding to monkey
CD16A and CD32A (Figure 2b). In contrast to the
decreased binding observed with human CD32B,
MGFc0264 shows increased binding to monkey CD32B
and this is most likely attributable to differences at posi-
tion 131 (R in human and H in cynomolgus).
Murine CD16 is a low-affinity activating FcgRt h a ti s
approximately 60% homologous to human CD32A but
that, similarly to human CD16A, is distributed on mur-
ine NK cells and mononuclear phagocytes [22]. Binding
of the optimized Fc domain of MGAH22 to murine
CD16 is reduced (Figure 2c) and this contrasts to its
increased binding to human or cynomolgus monkey
CD16A. As with human CD32B, the optimized Fc
domain imparts reduced binding to CD32, the mouse
inhibitory FcgR (mice lack a CD32A ortholog), and
reduced binding to murine CD64 and this contrasts
with the minimal change observed with human CD64.
Both WT and optimized human Fc domains bind simi-
larly to mouse FcgRIV, although MGAH22 shows
slightly improved binding (slower off-rate). FcgRIV is
another low-affinity activating FcgR most closely related
to human CD16A in sequence, but to human CD32A in
distribution, because expression is restricted to murine
myeloid cells and is absent on NK cells; furthermore,
data suggest a potential functional relationship to
human FcεRI [22,30,31].
MGAH22 enhances the antibody-dependent cell-mediated
cytotoxicity activity of effector cells expressing the
CD16A-158F variant
For ADCC assays, effector cells were isolated from
human donors of different CD16A genotypes. Compared
with RES120, MGAH22 showed increased maximum
lysis and lower effective concentration for 50% lysis
(EC50) with CD16A F/F or V/F effector cells (purified
NK cells) against JIMT-1 breast cancer cells (Figure 3a-
e). With CD16A V/V effector cells, MGAH22 exhibited
lower EC50 but was unaccompanied by enhanced maxi-
mum lysis. In these experiments, ch4D5-N297Q was
inactive, confirming the requirement for a functional Fc
domain.
MGAH22 mediates efficient antibody-dependent cell-
mediated cytotoxicity against tumor cells expressing low
HER2 levels
MGAH22 demonstrated ADCC activity with EC50 values
lower than those of RES120 against breast and non-
breast cancer cell lines encompassing a wide range of
surface HER2 expression with effector cells (PBMCs)
from CD16A F/F or V/F donors (Figure 3f-m). No activ-
ity occurred when a HER2-negative breast cancer cell
line (MDA-MB-468) [32] was tested (data not shown).
The increase in maximum lysis with MGAH22 was
inversely proportional to HER2 levels, and the greatest
enhancement occurred with cells expressing lower
HER2 densities. At very high HER2 levels, such as with
SKBR-3 target cells, no increase in maximum lysis was
observed with MGAH22; however, a substantial decrease
in EC50 was still observed.
Increased anti-tumor activity of MGAH22 in mice
transgenic for human CD16A-158F
While mice bearing human tumor xenografts are com-
monly used to demonstrate anti-tumor activity of
human IgG1 mAbs, mouse FcgRs are distributed and
bind human IgG1 differently than their human counter-
parts (compare Figures 2a and 2c). This hampers the
utilization of mouse xenograft models to assess the
functional properties of mAbs optimized for human
FcgR interactions. To ascertain the role of FcgRs in
MGAH22 anti-tumor activity, xenograft studies
employed three mouse strains: FcgR-WT mice (WT
murine FcgR repertoire), mCD16
-/- mice (lacking murine
CD16), and mCD16
-/- hCD16A
+ mice (lacking mCD16
but transgenic for human CD16A-158F, the low-binding
allele). In this transgenic mouse strain, human CD16A-
158F is expressed by NK cells and mononuclear phago-
cytes [25], similarly to its cell type-specific expression in
humans [33]. Although mFcgRIV expression is pre-
served, this transgenic mouse model effectively elimi-
nates the confounding factor caused by differential
binding to mCD16.
JIMT-1 cells, which are insensitive to direct inhibition
(Figure 1b), were selected for xenograft studies to elimi-
nate confounding components pertaining to the anti-
proliferative activity of anti-HER2 mAbs. This was con-
firmed by treating FcgR-WT mice bearing JIMT-1 xeno-
grafts with the Fc domain inactive ch4D5-N297Q mAb,
which showed no anti-tumor activity (Figure 4a), indi-
cating that only Fc-dependent mechanisms mediate
activity against these xenografts. When MGAH22 or
RES120 was administered to the same xenograft-bearing
FcgR-WT mice, tumor growth was modestly inhibited,
and the two antibodies were equally active. Administra-
tion of either mAb to mCD16
-/- tumor-bearing mice
resulted in no anti-tumor activity (Figure 4b), and this
suggests that mFcgRIV, in spite of its ability to bind to
WT and optimized Fc domains, plays no role in this
tumor model, possibly because of its lack of expression
on NK cells and its restricted expression to myeloid
cells.
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Page 6 of 14When administered to JIMT-1 xenograft-bearing
mCD16
-/- hCD16A
+ mice, MGAH22 exhibited enhanced
anti-tumor activity compared with RES120 (Figure 4c),
an activity attributable to the improved interaction
between its optimized Fc domain and the human
CD16A-158F (low-binding allele) receptor. In mCD16
-/-
hCD16A
+ mice with established JIMT-1 tumors,
MGAH22 exhibited significant anti-tumor activity at
weekly doses of 1 or 10 mg/kg (Figure 4e), whereas
RES120 exhibited only marginal anti-tumor activity at
10 mg/kg and no activity at 1 mg/kg (Figure 4d). These
data support the hypothesis that MGAH22 is more
active than an anti-HER2 mAb with a WT Fc domain,
such as trastuzumab.
Pharmacokinetics in cynomolgus monkeys
Pharmacokinetics of MGAH22 and RES120 were com-
pared after single or repeated administrations in cyno-
molgus monkeys. Serum concentration-versus-time
curves after a single dose of 50 mg/kg were biphasic,
and pharmacokinetic parameters, calculated using a
two-compartment elimination/distribution model, were
similar for the two antibodies in males and females,
except that the terminal elimination half-life of
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Figure 3 In vitro antibody-dependent cell-mediated cytotoxicity (ADCC) activity. (a-e) ADCC with JIMT-1 as target cells and purified natural
killer (NK) cells from two or three independent donors for each CD16A genotype (F/F, F/V, or V/V) as effectors using a 3:1 effector/target ratio. (f-
m) ADCC with breast and non-breast cancer cell lines expressing HER2 at different levels as target cells and peripheral blood mononuclear cells
from three to six independent CD16A-158F carriers as effectors using a 30:1 effector/target ratio. Fold increases in percentage maximal lysis by
MGAH22 relative to RES120 and EC50 values are plotted according to CD16A genotype of effectors (d, e) or number of HER2-binding sites per
target cell (l, m). Data are presented as mean ± standard error of the mean. EC50, effective concentration for 50% lysis; MGAH22, chimeric anti-
HER2 monoclonal antibody with an optimized Fc domain; RES120, chimeric anti-HER2 monoclonal antibody with wild-type human
immunoglobulin G 1 Fc domain.
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Page 7 of 14MGAH22 was approximately 20% shorter than that of
RES120 (9.3 to 9.7 versus 11.7 to 12 days) (Figure 5 and
Table 1). Two of six animals that received MGAH22
exhibited a rapid decline in serum concentration at days
22 to 29 and tested positive for anti-drug antibodies
(ADAs), whereas none of the six animals that received
RES120 were ADA-positive. In the repeat-dose study,
MGAH22 was administered weekly for 6 weeks at doses
of 15, 50, or 150 mg/kg, and animals in the recovery
groups were followed for 56 days after the last dose.
Values of Cmax (maximal serum concentration) and
AUC0-∞ (area under the curve from zero to infinity)
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Figure 4 In vivo efficacy. (a) Wild-type FcgR mice (10 per group): JIMT-1 cells implanted subcutaneously (s.c.) and monoclonal antibodies
(mAbs) at 4 mg/kg administered five times at weekly intervals beginning at day 0. The first day of significant reduction in tumor size occurred
at day 30 for both MGAH22 (P < 0.01) and RES120 (P < 0.01) compared with phosphate-buffered saline (PBS). (b) mCD16
-/- mice (11 per group):
JIMT-1 cells implanted s.c. and mAbs at 2 mg/kg administered six times at weekly intervals beginning at day 0. (c) mCD16
-/- hCD16A
+ mice (8
per group): JIMT-1 cells implanted s.c. and mAbs at 2 mg/kg administered six times at weekly intervals beginning at day 0. The first day of
significant reduction in tumor sizes occurred at day 37 for MGAH22 compared with PBS (P < 0.001), at day 44 for RES120 compared with PBS (P
< 0.01), and at day 61 for MGAH22 compared with RES120 (P < 0.05). (d, e) mCD16
-/- hCD16A
+ mice (10 per group): JIMT-1 cells implanted s.c.
and tumors of approximately 200 mm
3 allowed to form; RES120 (d) or MGAH22 (e) administered six times at weekly intervals beginning at day 6
at 0.01, 0.1, 1, or 10 mg/kg. The first day of significant reduction in tumor size occurred at day 32 for 1 or 10 mg/kg MGAH22 compared with
PBS (P < 0.01), at day 41 for 10 mg/kg RES120 compared with PBS, at day 47 for 1 mg/kg MGAH22 compared with 1 mg/kg RES120 (P < 0.05),
and at day 63 for 10 mg/kg MGAH22 compared with 10 mg/kg RES120 (P < 0.01). Data are presented as mean ± standard error of the mean.
The first days of significant reduction in tumor sizes are indicated for MGAH22 or RES120 compared with vehicle (*) and for MGAH22 compared
with RES120 (#). MGAH22, chimeric anti-HER2 monoclonal antibody with an optimized Fc domain; RES120, chimeric anti-HER2 monoclonal
antibody with wild-type human immunoglobulin G 1 Fc domain.
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Page 8 of 14following the first dose appeared to increase linearly but
were not dose-proportional after the sixth dose. Clear-
ance was more rapid after the first dose than the sixth
dose, and this likely reflects saturation of binding to tar-
get receptors. Terminal serum half-life was 7.3 to 8.9
days. One of the four animals in the low-dose recovery
group exhibited a rapid decline in serum MGAH22 at
the last few time points and tested positive for ADA at
56 days after the last dose, whereas ADA was not
observed in any of the eight animals in the two higher-
dose recovery groups; thus, incidence of ADA against
the Fc-engineered molecule was not common in mon-
keys receiving multiple doses. Overall, the pharmacoki-
netic parameters for MGAH22 in cynomolgus monkeys
are consistent with those of other anti-HER2 mAbs
[34,35].
Toxicology of MGAH22 in cynomolgus monkeys
MGAH22 recognizes cynomolgus HER2, and cross-reac-
tivity studies with MGAH22 and trastuzumab revealed
similar staining patterns against human and cynomolgus
tissue panels (data not shown). Cynomolgus monkeys
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0.0001
0.001
0.01
0.1
1
10
n
MGAH22 (male)
MGAH22 (female)
RES120 (male)
RES120 (female)
Days
m
g
/
m
L
B. Repeat dose
(15 mg/kg)
0 28 56 84
n n n n n n
Days
C. Repeat dose
(50 mg/kg)
0 28 56 84
n n n n n n
Days
D. Repeat dose
(150 mg/kg)
0 28 56 84
n n n n n n
Days
Figure 5 Pharmacokinetics in cynomolgus monkeys. Serum concentration-versus-time profiles for intravenous administration of MGAH22 or
RES120 at a single 50 mg/kg dose (a) or MGAH22 at 15 (b),5 0(c), or 150 (d) mg/kg weekly for 6 weeks. Data are presented as mean ±
standard error of the mean. MGAH22, chimeric anti-HER2 monoclonal antibody with an optimized Fc domain; RES120, chimeric anti-HER2
monoclonal antibody with wild-type human immunoglobulin G 1 Fc domain.
Table 1 Pharmacokinetic parameters for MGAH22 and RES120 in cynomolgus monkeys
Study Monoclonal antibody Dose, mg/kg Sex Cmax, mg/mL AUC0-¥, mg-hour/mL T1/2b, days Clearance, mL/hour Vss,m L
Single-dose RES120 50 Male 1.40 ± 0.32 285.7 ± 4.2 11.7 ± 2.4 0.44 ± 0.01 170 ± 36
Female 1.43 ± 0.05 311.8 ± 54.6 12.0 ± 2.3 0.41 ± 0.07 158 ± 15
MGAH22 50 Male 1.62 ± 0.10 294.1 ± 53.2 9.3 ± 1.8 0.43 ± 0.07 132 ± 2
Female 1.70 ± 0.14 314.2 ± 31.3 9.7 ± 1.1 0.40 ± 0.04 127 ± 8
Repeat-dose MGAH22 (first dose) 15 Male 0.43 ± 0.06 57.0 ± 11.2 5.6 ± 2.0 0.82 ± 0.18 148 ± 35
Female 0.43 ± 0.40 42.8 ± 9.7 5.1 ± 1.2 1.09 ± 0.24 144 ± 27
50 Male 1.37 ± 0.23 205.7 ± 127.0 6.9 ± 5.0 0.82 ± 0.28 161 ± 24
Female 2.85 ± 1.37 286.6 ± 98.2 6.6 ± 4.8 0.57 ± 0.21 109 ± 46
150 Male 4.10 ± 0.49 558.1 ± 168.6 7.3 ± 3.7 0.78 ± 0.23 176 ± 60
Female 6.22 ± 1.44 882.9 ± 347.7 7.9 ± 3.6 0.55 ± 0.32 127 ± 34
MGAH22 (sixth dose) 15 Male 0.89 ± 0.11 229.8 ± 82.1 8.9 ± 4.3 0.24 ± 0.12 66 ± 6
Female 0.98 ± 0.33 209.4 ± 110.4 8.7 ± 4.6 0.29 ± 0.16 90 ± 51
50 Male 4.90 ± 5.34 975.5 ± 747.1 8.8 ± 3.0 0.22 ± 0.13 65 ± 34
Female 7.20 ± 5.70 1,040.4 ± 657.6 7.3 ± 4.7 0.20 ± 0.12 41 ± 18
150 Male 6.87 ± 1.64 1,330.3 ± 456.7 7.3 ± 3.0 0.36 ± 0.13 81 ± 14
Female 11.00 ± 4.89 1,963.5 ± 1,273.1 8.8 ± 2.4 0.31 ± 0.19 73 ± 36
Data are presented as mean ± standard deviation. AUC0-¥, area under the curve from zero to infinity; Cmax, maximal serum concentration; MGAH22, chimeric anti-
HER2 monoclonal antibody with an optimized Fc domain; RES120, chimeric anti-HER2 monoclonal antibody with wild-type human immunoglobulin G 1 Fc
domain; T1/2b, elimination half-life; Vss, volume of distribution at steady state.
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Page 9 of 14express activating and inhibitory FcgRs with substantially
enhanced binding to the optimized Fc domain of
MGAH22 relative to the WT Fc domain (Figure 2b).
Although the increased binding to the inhibitory CD32B
receptor could limit toxicity, it is compensated by the
enhanced binding of the activating receptors, which is
greater than that observed with human orthologs. When
administered by intravenous infusion at a single 50 mg/
kg dose or at 6 weekly doses of 15, 50, or 150 mg/kg,
MGAH22 was well tolerated in male and female animals,
and there were no clinical signs or treatment-related
effects on food consumption, body weights, physical or
ophthalmic examinations, blood pressure or heart rate,
electrocardiogram, serum troponin I, hematology, serum
chemistry, coagulation, or urine analysis parameters at
any time during the study. There were no gross or micro-
scopic findings at terminal necropsy attributable to
MGAH22 administration and no findings in heart tissue.
Circulating NK cells (measured as CD3
-/CD159a
+ cells
by flow cytometry) were decreased, compared with pre-
dose levels, by an average of 51% (range of 40% to 65%)
in MGAH22-treated animals compared with 30% (range
of 18% to 43%) in vehicle-treated animals within 1 day
of dosing. Declines in NK cells were independent of
dose, smaller in magnitude (less than 30%) after subse-
quent administrations, and not associated with changes
in NK cell cytolytic activity when PBMCs from the trea-
ted monkeys were used as effector cells against K562
cells as targets (data not shown).
Low levels of IL-6 (Figure 6a), but not IL-2, IL-4, IL-5,
INF-g,o rT N F - a (data not shown), were transiently
induced within 4 hours of infusion of MGAH22,
RES120, or vehicle. From baseline levels of not more
than 3 pg/mL, mean peak serum IL-6 levels after the
f i r s ti n f u s i o nw e r e1 1t o3 2p g / m Lw i t hR E S 1 2 0o r
MGAH22 compared with 7 pg/mL with vehicle. After
the sixth infusion in the repeat-dose study, mean peak
s e r u mI L - 6l e v e l sf o ra l lM G A H 2 2g r o u p s( 7t o1 2p g /
mL) were comparable to those in the vehicle group (10
pg/mL). Magnitude and duration of IL-6 induction by
MGAH22 were dose-independent and comparable to
those observed with RES120, indicating that cytokine
release is not enhanced by the optimized Fc domain.
This observation was corroborated by measuring anti-
body-induced cytokine release from human PBMCs in
the presence or absence of immobilized HER2 antigen.
The three anti-HER2 mAbs (MGAH22, RES120, and
trastuzumab) induced similar levels of IL-6 (Figure 6b),
TNF-a, and IFN-g (data not shown) in the presence, but
not absence, of HER2 antigen.
Discussion
MGAH22 is a human/mouse chimeric IgG1 anti-HER2
antibody based on mouse clone 4D5, the precursor to
trastuzumab. MGAH22 was engineered to maintain the
antigen-binding properties of the original antibody while
optimizing its interactions with human FcgRs, important
mediators of antibody function in vivo. The engineered
Fc domain of MGAH22 imparts increased affinity for
both allelic variants of the low-affinity activating FcgR,
CD16A, and decreased affinity for the inhibitory FcgR,
CD32B. While maintaining the HER2-binding properties
and direct anti-proliferative activity of trastuzumab
against sensitive cell lines, these enhanced binding prop-
erties confer additional improvements in terms of
enhanced anti-tumor activity against HER2-expressing
tumor cell lines in vitro; the greatest improvement was
observed in ADCC activity against the lower (1+ and 2
+) HER2-expressing cell lines and/or with effector cells
isolated from human donors homozygous or heterozy-
gous for the low-binding allele (158F) of CD16A. In
vivo, MGAH22 exhibited enhanced anti-tumor activity
against a 2+ HER2-expressing cell line in mice geneti-
cally deficient for murine CD16 but transgenic for the
human CD16A-158F variant.
The FcgR-binding profile of MGAH22 has many
unique aspects. The increased binding affinity to CD16A
compares well with that observed with afucosylated tras-
truzumab [36] or other Fc-engineered mAbs [37-39].
The improvement in MGAH22 binding to the 158F
allele of human CD16A to levels exceeding those of the
WT Fc domain for the 158V allele suggests that
MGAH22 could provide benefit to patients of any
CD16A genotype, but particularly homozygotes or het-
erozygotes carrying the 158F variant, who have poorer
outcomes in response to trastuzumab treatment [11].
The increased CD16A binding also resulted in increased
effectiveness, particularly against tumor cells expressing
low levels of HER2. This suggests that MGAH22 can
induce productive synapse formation between tumor
and effector cells with fewer antibody-target interactions
on the tumor cell surface, presumably by recruiting
more Fc receptors on the effector cells per unit of bind-
ing or increasing the length of time the receptor is
engaged or both. Because the benefit of trastuzumab
therapy accrues only to patients with tumors that over-
express HER2 at the 3+ level or exhibit gene amplifica-
tion [3,5,40], this finding suggests that MGAH22 may
extend such advantages of anti-HER2 therapy to patients
whose tumors express low HER2 levels and who are not
thought to benefit from trastuzumab treatment.
CD16A is coexpressed with other FcgRs on mononuc-
lear phagocytes but is the only FcgR expressed by NK
cells. These cells are the major contributors to ADCC
activity in PBMCs under standard in vitro assay condi-
tions, a notion supported by the observation that
enhanced MGAH22-mediated ADCC was also observed
with purified NK cells. NK cells have been implicated as
Nordstrom et al. Breast Cancer Research 2011, 13:R123
http://breast-cancer-research.com/content/13/6/R123
Page 10 of 14important mediators of the anti-tumor activity of trastu-
zumab in patients with breast cancer. Trastuzumab
treatment is associated with increased numbers of
tumor-associated NK cells, and patients with responsive
tumors tend to have larger numbers of tumor-infiltrat-
ing NK cells [8,9]. Patients with higher NK cell numbers
exhibit higher levels of trastuzumab-mediated ADCC
activity, which has been associated with increased tumor
responsiveness [9,10]. This finding is consistent with the
association between responsiveness to trastuzumab
treatment and level of ADCC activity mediated by
CD16-expressing cells and CD16A genotype [11].
Another unique feature of the Fc domain of MGAH22
is its decreased binding to the CD32B inhibitory recep-
tor. Fc domains exhibiting decreased fucosylation, by
comparison, enhance binding only to CD16A [39,41],
and other mutations reported to increase binding to
activating receptors also demonstrate increased binding
to CD32B but to different extents, depending on the
mutations [37,38]. When co-engaged with an activating
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Figure 6 MGAH22-induced IL-6 release in vivo and in vitro. (a) Serum IL-6 levels in single- and repeat-dose studies in cynomolgus monkeys.
When MGAH22-treated groups were compared with RES120-treated groups (single-dose study) or with vehicle control group (repeat-dose
study), there were no statistically significant changes in IL-6 levels. (b) In vitro IL-6 release from human peripheral blood mononuclear cells
(PBMCs) incubated with the indicated antibodies on uncoated plates or plates coated with recombinant HER2 antigen. Statistically significant
changes in IL-6 levels (P = 0.0313) were noted for MGAH22 compared with RES120 at concentrations of 1 or 10 μg/mL in the presence of
immobilized HER2, but there were no significant differences between MGAH22 and trastuzumab. Data are presented as mean ± standard error
of the mean. IL-6, interleukin-6; MGAH22, chimeric anti-HER2 monoclonal antibody with an optimized Fc domain; RES120, chimeric anti-HER2
monoclonal antibody with wild-type human immunoglobulin G 1 Fc domain.
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Page 11 of 14FcgR on mononuclear phagocyte effectors, CD32B con-
fers an inhibitory signal that counters cell activation.
Although no clinical data on an association between
reduced CD32B binding and response to trastuzumab or
other mAbs are available, non-clinical studies show the
importance of Fc-mediated functions exerted by mono-
cytes and macrophages in vivo [42]. Enhanced anti-
tumor responses occur in mice genetically lacking
CD32B [7], and enhanced antigen delivery via immune
complexes that bind both activating and inhibitory
receptors occurs under conditions of CD32B blockade
[43-45]. These effects may contribute to the ability of
immunotherapy to break tolerance in cancer and induce
an adaptive immune response. Attempts at modeling
the CD32B-dependent component of MGAH22 action
in terms of effector cell function have been hampered
by the ineffective tumor cytotoxic activity of mononuc-
lear phagocytes in vitro (data not shown) and lack of a
suitable animal model. Nonetheless, a decline in binding
to CD32B is expected to be beneficial by increasing the
ratio of activating-to-inhibitory FcgR interactions.
In the selection of species for non-human primate
toxicology studies, both antigen expression and Fc/FcgR
interactions were considered. Tissue cross-reactivity stu-
dies with MGAH22 on human and cynomolgus tissue
panels revealed similar antigen distributions, which were
comparable to those observed with trastuzumab. Impor-
tantly, the binding profile of MGAH22 to cynomolgus
monkey FcgRs generally supports the use of this species
as a relevant toxicology model for the immune effector
function of this antibody. Although the engineered Fc
domain has increased binding to cynomolgus monkey
CD32B, which differs from its decreased binding to
human CD32B and may limit toxicity in monkeys, it has
increased binding to the invariant monkey CD16A and
CD32A receptors. Moreover, the binding affinities for
these activating FcgRs of monkeys exceed those for the
high-binding alleles of the human orthologs, a situation
that may counteract the potential inhibitory effect of
increased binding to monkey CD32B and be adequate
for evaluating potential toxic effects due to FcgR
engagement.
The MGAH22 Fc domain preserves FcRn binding,
which favors an extended serum half-life [46]. The term-
inal half-life of MGAH22 in cynomolgus was 7 to 9
days, approximately 20% shorter than that of RES120,
which contains the WT Fc domain. A similar decline in
half-life was observed when afucosylated trastuzumab,
exhibiting increased binding to hCD16A, was compared
with trastuzumab in hCD16A transgenic mice [36].
Except for a slightly shorter half-life, the pharmacoki-
netic profile of MGAH22 in cynomolgus monkeys is
comparable to that of other anti-HER2 mAbs [34,35].
Importantly, in the single- and repeat-dose toxicology
studies, there were no significant antibody-related clini-
cal observations or macro/microscopic findings. The
modest dose-independent decrease in circulating NK
cells was reminiscent of a similar observation in mon-
keys treated with an Fc domain-enhanced anti-CD19
mAb [37]. Given its transient nature, the phenomenon
likely results from margination of the NK cells. The Fc-
engineered MGAH22 mAb was not unusually immuno-
genic in monkeys, but owing to the lack of predictive
value of immunogenicity data in animals [47], the
potential incidence of immunogenicity in humans can-
not be extrapolated.
Cytokine release could be exacerbated by increased
binding to FcgRs. MGAH22 induced minimal levels of
just IL-6 in cynomolgus monkeys and IL-6, TNF-a,a n d
IFN-g from human PBMCs in vitro that were similar to
those induced by RES120 or trastuzumab, suggesting that
MGAH22 is unlikely to induce cytokines in patients to
levels any higher than those induced by trastuzumab. A
potential explanation is that cytokine release may relate
more to CD32A than CD16A. CD32A expression by
mononuclear phagocytes, but not NK cells, is consistent
with the spectrum of observed cytokines, which did not
include IL-2, an NK cell-derived cytokine. Binding of
MGAH22 to the prevalent CD32A-131H allele is
unchanged compared with WT Fc domains, whereas
binding to the rarer CD32A-131R allele is decreased, a
reflection of the high degree of homology between the
extracellular domain and Fc-binding interface of this var-
iant with CD32B (including the arginine at position 131,
which is shared by CD32B). While CD32A polymorphism
may contribute to outcomes in patients with trastuzu-
mab-treated metastatic breast cancer, its role is less pro-
nounced than that associated with CD16A polymorphism
[11]. Moreover, recent data suggest an association of the
131H allele of CD32A with the development of trastuzu-
mab-related cardiotoxicity [48]. Thus, the lack of
enhanced binding to either of the CD32A alleles may be
favorable to the safety profile of MGAH22.
Other novel HER2-directed agents are undergoing
clinical development. A trastuzumab-drug conjugate, T-
DM1, designed to deliver a cytotoxic molecule into
HER2-overexpressing cells via receptor-mediated endo-
cytosis [49], has shown a significant advantage in
advanced breast cancer, although its benefits appear to
be restricted to patients with HER2 3+ or gene-ampli-
fied tumors [50]. In this context, MGAH22 may have
particular utility in patients with low HER2-expressing
tumors. An afucosylated version of trastuzumab with
increased anti-tumor effector function has also been
described [36]. However, MGAH22, by exhibiting
diminished binding to the inhibitory FcgR, CD32B, dif-
fers from afucosylated trastuzumab, which exhibits a
slight increase in binding to this inhibitory receptor.
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tory FcgR, would be expected to exhibit additional favor-
able properties in the presence of mononuclear
phagocytic effector cells and potentially further
enhanced efficacy against low HER2-expressing tumors
or tumors resistant to trastuzumab therapy.
Conclusions
The favorable safety profile of MGAH22 is reflected by
its ‘no observed adverse effect level’ (NOAEL) in cyno-
molgus monkeys of 150 mg/kg. The minimal effective
human equivalent dose is approximately 0.1 mg/kg, esti-
mated from a minimum effective dose of 1 mg/kg in
xenograft models with human CD16A transgenic mice
(10-fold lower than that of the corresponding WT
mAb). Based on these considerations, a phase 1 dose-
escalation study with MGAH22 doses ranging from 0.1
to 15 mg/kg has been initiated in patients with HER2-
expressing tumors.
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